Triple therapy superior to dual therapy in HCV
As reported in Mayo Clinic Proceedings, treatment of hepatitis C virus-infected patients with triple therapy (pegylated-interferon, ribavirin, and teleprevir) is more effective than dual therapy (pegylated-interferon and ribavirin). Specifically, a sustained virologic response was achieved in 51% of treatment-naïve patients, 67% of patients with a prior non-response and 56% of patients with a prior relapse of patients treated with triple therapy compared to 37%, 11%, and 27% of patients treated with dual therapy, respectively.
Combination tiotropium + formoterol superior to tiotropium alone in COPD patients
As reported in Pulmonary Pharmacology & Therapeutics, combination tiotropium (18 mcg) + formoterol (12 mcg) was superior to tiotropium alone in COPD (n=44) patients inadequately controlled with bronchodilator monotherapy. Combination therapy resulted in an increased bronchodilator response (FEV1 and FVC) and a maximum change in FEV1 and FVC over 24 h.
Belimumab safe and effective in childhood-onset SLE
As reported in Arthritis and Rheumatology, belimumab (a human monoclonal antibody targeting soluble B-lymphocyte stimulator) is effective and well-tolerated in children with SLE (n=7). The mean follow-up was 9.3 months. The SLEDAI decreased from 6.4 to 4 and 57% of recipients were able to taper steroids. Clinical response was evident by 3 months.